Free tool
FAERS Monitor: Asparlas
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761102 or its brand name (Asparlas, Calaspargase Pegol-Mknl). Reports on generic versions are filed under their own applications.
Reports
804
Serious
736
92% of reports
Hospitalization
340
Death reported
65
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypersensitivity211
- anaphylactic reaction103
- febrile neutropenia71
- pancreatitis71
- infusion related reaction67
- hypertriglyceridaemia56
- vomiting36
- tachycardia28
- neutropenia26
- pancytopenia25
- cough23
- hyperglycaemia23
- nausea23
- sepsis21
- hepatotoxicity20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 5 |
| 2023 | 187 |
| 2024 | 284 |
| 2025 | 158 |
| 2026 | 170 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,355 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypertriglyceridaemiaSignal | 56 | 252.7 | 196.0 | 13,658 |
| anaphylactic reactionSignal | 103 | 48.9 | 40.8 | 4,784 |
| pancreatitisSignal | 71 | 35.2 | 28.2 | 2,327 |
| hypersensitivitySignal | 211 | 29.8 | 26.5 | 5,883 |
| febrile neutropeniaSignal | 71 | 28.0 | 22.4 | 1,828 |
| infusion related reactionSignal | 67 | 26.5 | 21.0 | 1,620 |
| hepatotoxicitySignal | 20 | 23.5 | 15.3 | 409 |
| hyperglycaemiaSignal | 23 | 16.5 | 11.0 | 320 |
| pancytopeniaSignal | 25 | 11.7 | 8.0 | 235 |
| tachycardiaSignal | 28 | 8.2 | 5.7 | 172 |
| neutropeniaSignal | 26 | 5.0 | 3.4 | 80 |
| sepsisSignal | 21 | 4.9 | 3.2 | 62 |
| coughSignal | 23 | 2.1 | 1.4 | 13 |
| vomitingSignal | 36 | 2.0 | 1.5 | 17 |
| nausea | 23 | 0.8 | 0.5 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.